ArticleStem cells and development2012
Efficient derivation and genetic modifications of human pluripotent stem cells on engineered human feeder cell lines.
Article in Stem cells and development, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Spatial and Temporal Development of Müller Glial Cells in hiPSC-Derived Retinal Organoids Facilitates the Cell Enrichment and Transcriptome Analysis.Frontiers in cellular neuroscience · 2022Article
- Targeting specificity of APOBEC-based cytosine base editor in human iPSCs determined by whole genome sequencing.Nature communications · 2019Article
- Role of iPSC-derived pericytes on barrier function of iPSC-derived brain microvascular endothelial cells in 2D and 3D.Fluids and barriers of the CNS · 2019Article
- Wnt3a Ectopic Expression Interferes Axonal Projection and Motor Neuron Positioning During the Chicken Spinal Cord Development.Journal of molecular neuroscience : MN · 2018Article
- Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Human Brain Microvascular Endothelial Cells Derived from the BC1 iPS Cell Line Exhibit a Blood-Brain Barrier Phenotype.PloS one · 2016Article
- Wnt3a: functions and implications in cancer.Chinese journal of cancer · 2015Review
- Efficient and allele-specific genome editing of disease loci in human iPSCs.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.World journal of diabetes · 2014Review
- Whole-genome sequencing identifies genetic variances in culture-expanded human mesenchymal stem cells.Stem cell reports · 2014Article
- Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013.Annals of biomedical engineering · 2014Review
- Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells.Hepatology (Baltimore, Md.) · 2013Article
- Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression.Nature protocols · 2012Article
- Promise and challenges of human iPSC-based hematologic disease modeling and treatment.International journal of hematology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
Abstract
Derivation of pluripotent stem cells (iPSCs) induced from somatic cell types and the subsequent genetic modifications of disease-specific or patient-specific iPSCs are crucial steps in their applications for disease modeling as well as future cell and gene therapies. Conventional procedures of these processes require co-culture with primary mouse embryonic fibroblasts (MEFs) to support self-renewal and clonal growth of human iPSCs as well as embryonic stem cells (ESCs). However, the variability of MEF quality affects the efficiencies of all these steps. Furthermore, animal sourced feeders may hinder the clinical applications of human stem cells. In order to overcome these hurdles, we established immortalized human feeder cell lines by stably expressing human telomerase reverse transcriptase, Wnt3a, and drug resistance genes in adult mesenchymal stem cells. Here, we show that these immortalized human feeders support efficient derivation of virus-free, integration-free human iPSCs and long-term expansion of human iPSCs and ESCs. Moreover, the drug-resistance feature of these feeders also supports nonviral gene transfer and expression at a high efficiency, mediated by piggyBac DNA transposition. Importantly, these human feeders exhibit superior ability over MEFs in supporting homologous recombination-mediated gene targeting in human iPSCs, allowing us to efficiently target a transgene into the AAVS1 safe harbor locus in recently derived integration-free iPSCs. Our results have great implications in disease modeling and translational applications of human iPSCs, as these engineered human cell lines provide a more efficient tool for genetic modifications and a safer alternative for supporting self-renewal of human iPSCs and ESCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.